Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia

Blood

Volumn 117, Issue 7, 2011, Pages 2265-2274

  Kuzmina, Zoya ^a   Greinix, Hildegard T ^a   Weigl, Roman ^a   Körmöczi, Ulrike ^b   Rottal, Arno ^b   Frantal, Sophie ^a   Eder, Sandra ^a   Pickl, Winfried F ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD19 ANTIBODY; CD27 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOSPORIN; IMMUNOGLOBULIN G; METHOTREXATE; MYCOPHENOLIC ACID;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL SUBPOPULATION; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSGAMMAGLOBULINEMIA; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PRIORITY JOURNAL;

EID: 79951842596     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-295766     Document Type: Article

References (50)

1. Lee SJ, Vogelsang G, Gilman A, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002;8(1):32-39. (Pubitemid 34141549)
2. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1):14-21.
3. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004;125(4):435-454. (Pubitemid 38916189)
4. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
5. Roquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation: a study of 53 long-term-surviving patients. Transplantation. 1988;46(2):238-240.
6. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22(9):873-881. (Pubitemid 28499360)
7. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjogren's syndrome and scleroderma. Br J Haematol. 1987;66(1):45-47. (Pubitemid 17071187)
8. Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T cell depleted bone marrow transplantation. Bone Marrow Transplant. 1996;17(11):1093-1099. (Pubitemid 26235860)
9. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood. 2005;105(12):4885-4891. (Pubitemid 40807318)
10. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-versus-host disease is associated with autoimmune-like thrombocytopenia. Blood. 1989;73(4):1054-1058. (Pubitemid 19078388)
11. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(1 suppl 1):S146-S151.
12. Schultz KR. Pathophysiology of chronic graft versus host disease. In: Vogelsang GB, Pavletic SZ, eds. Chronic Graft Versus Host Disease. Cambridge, United Kingdom: Cambridge University Press; 2009:17-30.
13. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973-2978. (Pubitemid 40446295)
14. + B cells specify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(2):208-219.
15. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113(16):3865-3874.
16. Warnatz K, Wehr C, Drager R, et al. Expansion of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. Immunobiology. 2002;206(5):502-513. (Pubitemid 36192909)
17. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005;105(11):4390-4398. (Pubitemid 40720786)
18. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A. 2006;103(7):2262-2267. (Pubitemid 43271658)
19. Cuss AK, Avery DT, Cannons JL, et al. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol. 2006;176(3):1506-1516. (Pubitemid 43134294)
20. Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In: Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease. New York, NY: Marcel Dekker; 1997:257-289.
21. Kalhs P, Panzer S, Kletter K, et al. Functional asplenia after bone marrow transplantation: a late complication related to extensive chronic graft-versus-host disease. Ann Intern Med. 1988;109(6):461-464.
22. Storek J, Witherspoon RP, Webb D, Storb R. Lack of B cells in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol. 1996;52(2):82-89. (Pubitemid 26175047)
23. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
24. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-762. (Pubitemid 44061381)
25. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol. 2001;115(3):630-641. (Pubitemid 34015656)
26. She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(4):386-397. (Pubitemid 46421893)
27. Shimabukuro-Vornhagen A, Hallek MJ, Storb R, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009;114(24):4919-4927.
28. Witherspoon R, Storb R, Ochs H, Fluornoy N, Kopecky KJ, Sullivan KM. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood. 1981;58(2):360-368. (Pubitemid 11047356)
29. Hammarstrom V, Pauksen K, Svensson H, Lönnqvist B, Simonsson B, Ringdén O. Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients. Transplantation. 2000;69(8):1582-1586.
30. Cuthbert R, Iqbal A, Gates A, Toghill P, Russell N. Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol. 1995;48(3):257-259.
31. Noel DR, Witherspoon RP, Storb R, et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation of 56 long-term survivors. Blood. 1978;51(6):1087-1105. (Pubitemid 8344650)
32. Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San Miguel J. Chronic graft-versus-host disease. Drugs. 2006;66(8):1041-1057.
33. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood. 2008;111(6):3276-3285.
34. Patriarca F, Skert C, Sperotto A, Treister N, Woo SB, Bienfang D. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol. 2006;34(3):389-396.
35. D'Orsogna LJ, Wright MP, Krueger RG, et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol Blood Marrow Transplant. 2009;15(7):795-803.
36. Glas AM, van Montfort EH, Storek J, et al. B-cell-autonomous somatic mutation deficit following bone marrow transplant. Blood. 2000;96(3):1064-1069. (Pubitemid 30616874)
37. Carsetti R, Rosado MM, Donnanno S, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol. 2005;115(2):412-417. (Pubitemid 40215112)
38. Corre E, Carmagnat M, Busson M, et al. Long-term immune deficiency after allogeneic stem cell transplantation: B cell deficiency is associated with late infections. Haematologica. 2010;95(6):1025-1029.
39. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374-1377. (Pubitemid 37075812)
40. Keenan RA, Riva A, Corleis B, et al. Censoring of autoreactive B cell development by the pre-B cell receptor. Science. 2008;321(5889):696-699.
41. Tussiwand R, Bosco N, Ceredig R, Rolink AG. Tolerance checkpoints in B-cell development: Johnny B good. Eur J Immunol. 2009;39(9):2317-2324.
42. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491-502.
43. Walter JE, Rucci F, Patrizi L, et al. Expansion of immunoglobulin- secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. J Exp Med. 2010;207(7):1541-1554.
44. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785-798. (Pubitemid 38757447)
45. Hondowicz BD, Alexander ST, Quinn WJ, et al. The role of BlyS/BlyS receptors in anti-chromatin B cell regulation. Int Immunol. 2007;19(4):465-475. (Pubitemid 46523394)
46. Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev. 2008;223(1):156-174. (Pubitemid 351986170)
47. Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C. High serum levels of BAFF, APRIL and TACI in common variable immunodeficiency. Clin Immunol. 2007;124(2):182-189. (Pubitemid 47059040)
48. Winstead CJ, Reilly CS, Moon JJ, et al. CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia. J Immunol. 2010;184(9):4749-4760.
49. Kainulainen L, Varpula M, Liippo K, Svedström E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031-1036. (Pubitemid 29532125)
50. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302(3):306-314.